Current guidelines for management of hepatitis B and TB in patients with IBD do not emphasize the risks of thiopurine usage [11]; however, the increased risks of TB and hepatitis B associated with combined treatment with immunosuppressive agents (including thiopurine, steroids, and anti-TNF-α agents) has been reported [32]. This evidence concerns the gene TNF and tuberculosis.